40 Chapter 2 Table 2: Glucose changes before and during treatment First Author (Year) Sample Size Time of Glucose Estimation Baseline DM (%) Baseline IGT (%) Participants at Followup (N) % DM at Follow-Up % IGT at Follow-up Purohit, S D (1984) 57 0, 7, 30 days - 10.0 0 0.0 0.0 Singh, M.M (1984) 52 0, 4, 8, 12 weeks 3.8 44.2 52 1.9 11.5 Oluboyo, P.O (1990) 54 0, 3, 3 months PT# 5.6 37.0 53 1.9 9.3 Jawad, F (1995) 106 0, ET 19.8 29.2 23 21.7 21.7 Basoglu, O.K (1999) 58 0, 3 months 8.6 10.3 58 0 0 Tarbasi, P (2014) 158 0, 3 months 0 31.0 158 24.0 34 Akinlade, K.S*(2016) 21 0, 2, 4, 6 months PT - - - - Boillat-Blanco, N (2016) ** 530 0, ET 6.8 24.3 378 1.4 10 Lin, Y (2017) 232 0, 2, 6 months 0 7.3 232 0 3.0 Moreira, J (2018) 473 0, 3, 6 months, ET, PT 2.1 10.4 426 5.4 - Diarra, B (2019) 201 0, 2, 5 months 5.5 3.0 190 0 - Krishnappa, D (2019) 582 0, ET, PT 7.0 4 579 - 1.5 Habib, S.S (2020) 6312 0, 3 months 24 32 502 - 42.0 Kubjane, M (2020) 850 0, 3 months 11.9 46.9 276 9.3 21.5 *Two months follow-up showed a significant reduction in mean HbA1c. No values were indicated. **Reported values are for 2-hCG (two-hour capillary glucose). #In those with abnormal results. ET – End of treatment; PT – Post-treatment. Follow-up glucose at 30 days and two months was grouped with three months
RkJQdWJsaXNoZXIy MTk4NDMw